Said M Elshafae1,2,3, Wessel P Dirksen1,4, Aylin Alasonyalilar-Demirer1,5, Justin Breitbach1, Shiyu Yuan6, Noriko Kantake6, Wachiraphan Supsavhad7, Bardes B Hassan1,8, Zayed Attia1,9, Lucas B Alstadt1, Thomas J Rosol6. 1. Department of Veterinary Biosciences, College of Veterinary Medicine, The Ohio State University, Columbus, Ohio. 2. Department of Pathology, Faculty of Veterinary Medicine, Benha University, Benha, Egypt. 3. Department of Neuroscience and Pharmacology, Carver College of Medicine, University of Iowa, Iowa City, Iowa. 4. Department of Veterinary Clinical Sciences, College of Veterinary Medicine, The Ohio State University, Columbus, Ohio. 5. Department of Pathology, Faculty of Veterinary Medicine, Bursa Uludag University, Bursa, Turkey. 6. Department of Biomedical Sciences, Heritage College of Osteopathic Medicine, Ohio University, Athens, Ohio. 7. Department of Pathology, Faculty of Veterinary Medicine, Kasetsart University, Bangkok, Thailand. 8. Department of Pathology, Faculty of Veterinary Medicine, Cairo University, Giza, Egypt. 9. Department of Animal Medicine and Infectious Diseases, Faculty of Veterinary Medicine, Sadat City University, Sadat City, Egypt.
Abstract
BACKGROUND: Osteoblastic bone metastasis represents the most common complication in men with prostate cancer (PCa). During progression and bone metastasis, PCa cells acquire properties similar to bone cells in a phenomenon called osteomimicry, which promotes their ability to metastasize, proliferate, and survive in the bone microenvironment. The mechanism of osteomimicry resulting in osteoblastic bone metastasis is unclear. METHODS: We developed and characterized a novel canine prostatic cancer cell line (LuMa) that will be useful to investigate the relationship between osteoblastic bone metastasis and osteomimicry in PCa. The LuMa cell line was established from a primary prostate carcinoma of a 13-year old mixed breed castrated male dog. Cell proliferation and gene expression of LuMa were measured and compared to three other canine prostatic cancer cell lines (Probasco, Ace-1, and Leo) in vitro. The effect of LuMa cells on calvaria and murine preosteoblastic (MC3T3-E1) cells was measured by quantitative reverse-transcription polymerase chain reaction and alkaline phosphatase assay. LuMa cells were transduced with luciferase for monitoring in vivo tumor growth and metastasis using different inoculation routes (subcutaneous, intratibial [IT], and intracardiac [IC]). Xenograft tumors and metastases were evaluated using radiography and histopathology. RESULTS: After left ventricular injection, LuMa cells metastasized to bone, brain, and adrenal glands. IT injections induced tumors with intramedullary new bone formation. LuMa cells had the highest messenger RNA levels of osteomimicry genes (RUNX2, RANKL, and Osteopontin [OPN]), CD44, E-cadherin, and MYOF compared to Ace-1, Probasco, and Leo cells. LuMa cells induced growth in calvaria defects and modulated gene expression in MC3T3-E1 cells. CONCLUSIONS: LuMa is a novel canine PCa cell line with osteomimicry and stemness properties. LuMa cells induced osteoblastic bone formation in vitro and in vivo. LuMa PCa cells will serve as an excellent model for studying the mechanisms of osteomimicry and osteoblastic bone and brain metastasis in prostate cancer.
BACKGROUND:Osteoblastic bone metastasis represents the most common complication in men with prostate cancer (PCa). During progression and bone metastasis, PCa cells acquire properties similar to bone cells in a phenomenon called osteomimicry, which promotes their ability to metastasize, proliferate, and survive in the bone microenvironment. The mechanism of osteomimicry resulting in osteoblastic bone metastasis is unclear. METHODS: We developed and characterized a novel canineprostatic cancer cell line (LuMa) that will be useful to investigate the relationship between osteoblastic bone metastasis and osteomimicry in PCa. The LuMa cell line was established from a primary prostate carcinoma of a 13-year old mixed breed castrated male dog. Cell proliferation and gene expression of LuMa were measured and compared to three other canineprostatic cancer cell lines (Probasco, Ace-1, and Leo) in vitro. The effect of LuMa cells on calvaria and murine preosteoblastic (MC3T3-E1) cells was measured by quantitative reverse-transcription polymerase chain reaction and alkaline phosphatase assay. LuMa cells were transduced with luciferase for monitoring in vivo tumor growth and metastasis using different inoculation routes (subcutaneous, intratibial [IT], and intracardiac [IC]). Xenograft tumors and metastases were evaluated using radiography and histopathology. RESULTS: After left ventricular injection, LuMa cells metastasized to bone, brain, and adrenal glands. IT injections induced tumors with intramedullary new bone formation. LuMa cells had the highest messenger RNA levels of osteomimicry genes (RUNX2, RANKL, and Osteopontin [OPN]), CD44, E-cadherin, and MYOF compared to Ace-1, Probasco, and Leo cells. LuMa cells induced growth in calvaria defects and modulated gene expression in MC3T3-E1 cells. CONCLUSIONS:LuMa is a novel canine PCa cell line with osteomimicry and stemness properties. LuMa cells induced osteoblastic bone formation in vitro and in vivo. LuMa PCa cells will serve as an excellent model for studying the mechanisms of osteomimicry and osteoblastic bone and brain metastasis in prostate cancer.
Authors: W S Simonet; D L Lacey; C R Dunstan; M Kelley; M S Chang; R Lüthy; H Q Nguyen; S Wooden; L Bennett; T Boone; G Shimamoto; M DeRose; R Elliott; A Colombero; H L Tan; G Trail; J Sullivan; E Davy; N Bucay; L Renshaw-Gegg; T M Hughes; D Hill; W Pattison; P Campbell; S Sander; G Van; J Tarpley; P Derby; R Lee; W J Boyle Journal: Cell Date: 1997-04-18 Impact factor: 41.582
Authors: Fan Yeung; Wai K Law; Ching-Hua Yeh; Jennifer J Westendorf; Ye Zhang; Ruoxiang Wang; Chinghai Kao; Leland W K Chung Journal: J Biol Chem Date: 2001-10-29 Impact factor: 5.157
Authors: Leonard J Deftos; Israel Barken; Douglas W Burton; Robert M Hoffman; Jack Geller Journal: Biochem Biophys Res Commun Date: 2005-02-11 Impact factor: 3.575
Authors: Akeila Bellahcène; Vincent Castronovo; Kalu U E Ogbureke; Larry W Fisher; Neal S Fedarko Journal: Nat Rev Cancer Date: 2008-03 Impact factor: 60.716
Authors: L F Brown; A Papadopoulos-Sergiou; B Berse; E J Manseau; K Tognazzi; C A Perruzzi; H F Dvorak; D R Senger Journal: Am J Pathol Date: 1994-09 Impact factor: 4.307
Authors: Eduardo de Paula Nascente; Renée Laufer Amorim; Carlos Eduardo Fonseca-Alves; Veridiana Maria Brianezi Dignani de Moura Journal: Cancers (Basel) Date: 2022-05-31 Impact factor: 6.575
Authors: Toby Ryman-Tubb; Jennifer H Lothion-Roy; Veronika M Metzler; Anna E Harris; Brian D Robinson; Albert A Rizvanov; Jennie N Jeyapalan; Victoria H James; Gary England; Catrin S Rutland; Jenny L Persson; Lukas Kenner; Mark A Rubin; Nigel P Mongan; Simone de Brot Journal: Vet Med Sci Date: 2021-10-10